OncLive SOSS

Clinical Advances in Nasopharyngeal Carcinoma - Episode 6

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

September 4, 2024

Barbara Burtness, MD, Victoria M. Villaflor, MD, Shravan Kandula, MD

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma

EP. 3: Overview of the JUPITER and POLARIS-2 Trials

EP. 4: Value of PD-L1 Biomarker in NPC

EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

EP. 7: Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

EP. 8: Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

EP. 9: Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

EP. 10: Clinical Scenario: Locally Recurrent NPC

EP. 11: Clinical Scenario: Metastatic EBV-Positive NPC

Video content above is prompted by the following:

Is there a specific patient population that might benefit from this treatment?
Are there any external factors that may impact your treatment selection? Are you monitoring your patients for EBV titer?

x